Sentences with phrase «drugs in human patients»

Developing «designer» drugs is hard, and expensive, and testing drugs in human patients is the most expensive part.

Buoyed by these results, Dana - Farber researchers are working to create a derivative of dBET1 that can be used as a drug in human patients — and to extend the conjugate strategy for the treatment of other cancers and other genetically - caused diseases.

A phase - 1 clinical trial of the drug in human patients with pulmonary hypertension is expected to begin this winter.

Not exact matches

Valeri said drugs that work in mice have only proved effective in 60 to 70 percent of human patients.

Drugs that worked in the microtumor worked 88 percent of the time on humans, and drugs that failed in the microtumor failed 100 percent of the time in the patDrugs that worked in the microtumor worked 88 percent of the time on humans, and drugs that failed in the microtumor failed 100 percent of the time in the patdrugs that failed in the microtumor failed 100 percent of the time in the patient.

No. 2: Alzheimer's disease treatment nets a breakthrough Roughly 99 % of all Alzheimer's drugs to enter human trials have ended up in the trash heap, but trials are under way evaluating drugs that could soon reshape patient treatment.

Judge Miner, writing for the majority in the Second Circuit, asked: «What concern prompts the state to interfere with a mentally competent patient's «right to define [his] own concept of existence, of meaning, of the universe, and of the mystery of human life,» when the patient seeks to have drugs prescribed to end life during the final stages of a terminal illness?»

Before joining local government, he worked for a decade in human services, including counseling HIV and AIDS patients, and those with drug and alcohol issues.

«Acute repeated spikes in blood sugar that you see with each dose of this drug have long - term impacts — and can predispose patients to the development of insulin - resistance Type 2 diabetes and cardiovascular disease,» said David Wright, associate professor in the Department of Human Health and Nutritional Sciences and corresponding author of the paper.

A dozen human studies of MDMA, LSD, a powerful African drug called ibogaine and psilocybin, from so - called «magic mushrooms,» are now under way, testing the once - stigmatized drugs as treatments for not only PTSD, but also cluster headaches and addiction, as well as anxiety and depression in cancer patients.

He says his team is so confident with its results that it plans to petition the Food and Drug Administration this fall to test isradipine's effectiveness in human Parkinson's patients, because the drug has already been approved for human Drug Administration this fall to test isradipine's effectiveness in human Parkinson's patients, because the drug has already been approved for human drug has already been approved for human use.

Ubogu says the findings are very exciting, as they provide knowledge of leukocyte trafficking in human nerves, but more work needs to be done in affected patients to develop an effective drug.

At the patient safety charity, Safer Medicines, we believe this goal is most likely to be achieved through a greatly increased focus on human, rather than animal, biology in preclinical drugs tests.

GTC recognized the need to demonstrate on its own the potential for the technology and, in the late 1990s, began a clinical trial of human antithrombin for patients undergoing bypass surgery who develop resistance to the anticoagulant drug heparin.

These techniques include: human tissue created by reprogramming cells from people with the relevant disease (dubbed «patient in a dish»); «body on a chip» devices, where human tissue samples on a silicon chip are linked by a circulating blood substitute; many computer modelling approaches, such as virtual organs, virtual patients and virtual clinical trials; and microdosing studies, where tiny doses of drugs given to volunteers allow scientists to study their metabolism in humans, safely and with unsurpassed accuracy.

The journal provides cutting - edge research including results from animal models that are likely to apply to patients, studies in human tissue that provide new information about therapies or disease, and innovative reports of drug discovery and development.

Still, Zon cautions that not all human drugs work in zebrafish, so «we need to study a lot more patients to see, in a broad view, how this approach performs.»

Those false lines were used in the early trials of two drugs that were later tested in human patients with thyroid cancer.

The common pathway found in mouse models was also found in human tumors, suggesting that resistance could indeed be blocked in patients with the same drug as in mice.

«Next steps are to further explore this possibility in human trials in order to assess if it will help patients, but these two drugs make sense from a variety of studies and we find that they act together through multiple mechanisms to control cancer growth in the laboratory.»

A small dose of 1.56 µM, which is approximately equivalent to a daily dose of the drug in a human cancer patients, increased the fruit flies» average life expectancy by 8 %.

Mathias Uhlen, director of the Human Protein Atlas project and co-author of the paper, says: «I am extremely pleased that the resource created through the Human Protein Atlas effort has been used in the analysis of clinical data obtained from liver disease patients and that this analysis has led to the identification of liver - specific drug targets that can be used for treatment of this clinically important patient group.»

In order to test their hypothesis in a model that more closely mimicked human disease, the researchers also tested the two drugs side - by - side on slices of tumors removed from patients during radical prostatectomIn order to test their hypothesis in a model that more closely mimicked human disease, the researchers also tested the two drugs side - by - side on slices of tumors removed from patients during radical prostatectomin a model that more closely mimicked human disease, the researchers also tested the two drugs side - by - side on slices of tumors removed from patients during radical prostatectomy.

To see if PGD and the pentose phosphate pathway were tied to the epigenetic changes the researchers had detected in distant metastases, they treated tumor cells from different sites in a single patient with the drug 6 - aminonicotinamide (6AN), which is known to inhibit PGD but is not used in humans because of its severe side effects.

Additional experiments using a combination of maraviroc and a drug that blocks the VEGF protein suggest that the treatment duo could be an effective way to prevent metastatic disease in human breast cancer patients, according to the researchers.

Clinicians treating patients suffering from Middle East respiratory syndrome (MERS) currently have no drugs specifically targeted to the MERS coronavirus (MERS - CoV), a virus first detected in humans in 2012 that has since caused 614 laboratory - confirmed infections, including 181 that were fatal, according to the World Health Organization.

«A significant amount of work remains in the development of teixobactin as a therapeutic antibiotic for human use — we are probably around six to ten years off a drug that doctors can prescribe to patients — but this is a real step in the right direction and now opens the door for improving our in vivo analogues.»

2015 will see the start of the first human clinical trial of a gene silencing or huntingtin - lowering drug, which specifically aims to reduce production of mutant huntingtin in the brains of HD patients.

When the gel was incubated in synovial fluid from a healthy human joint, drug release was minimal, but when incubated in synovial fluid from a patient with rheumatoid arthritis, the drug was readily released from the hydrogel.

However the fact that Ciclopirox is already approved for treatment of patients by the FDA and by its European counterpart, the EMA, and therefore considered safe for human use, may eliminate much of the time and expense ordinarily involved in the drug development process.

In a letter published in the cancer journal Annals of Oncology, researchers led by Professor Jean - Philippe Spano, head of the medical oncology department at Pitie - Salpetriere Hospital AP - HP in Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapIn a letter published in the cancer journal Annals of Oncology, researchers led by Professor Jean - Philippe Spano, head of the medical oncology department at Pitie - Salpetriere Hospital AP - HP in Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapin the cancer journal Annals of Oncology, researchers led by Professor Jean - Philippe Spano, head of the medical oncology department at Pitie - Salpetriere Hospital AP - HP in Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapin Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapin the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapin the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapy.

Previous studies have shown the drug to be effective at spurring new bone growth in mice and in humans with osteoporosis, and a U-M research team believes that it may spur new growth in brittle bone disease patients as well.

«Overall, these drug responses in cave fish are very similar to what you see in human patients,» he said last week at the meeting in Fayetteville.

More animal studies would be needed to move this drug toward human clinical trials, but «what we hope is that we could use this drug to intervene in patients who have had an episode of prolonged seizures and give it to them briefly following that episode to protect them from becoming epileptic,» said James McNamara, M.D., a professor in the departments of neurobiology and neurology at Duke University.

Despite encouraging evidence from animal studies that it clears amyloid from the brain, when it came to clinical improvements in human patients the drug proved no better than placebo in two phase III clinical trials.

Specifically, they tested new drugs in zebrafish, a small, tropical fish genetically similar to humans, whose brains can develop seizures in a manner similar to patients with epilepsy.

I have been especially interested in testing drugs that can inhibit MMPs in cancer models and in understanding why such drugs have not been effective in human cancer patients.

In a 1988 paper summarizing his findings, Fiebig concluded that xenograft mice were wonderful models for broadly testing new drugs against human tumors, but they «can not be used as a clinical routine method» for predicting patient treatment.1 The idea of using xenograft mice as personal avatars for cancer patients was discarded.

These instruments have formed the foundation for the biochemistry cores of two NIH Centers of Excellence (the NIAAA - funded TSRI Alcohol Research Center and the National Institute on Drug Abuse [NIDA]- funded Scripps Center for Cannabis Addiction Neurobiology) and have directly supported other ongoing projects at TSRI (the Methamphetamine NeuroAIDS Research Program, NIDA - funded projects on immunopharmacotherapy [Taffe and Janda laboratories], a project with Dr. Steve Poceta to measure human lumbar cerebrospinal fluid in Parkinson's patients with Restless Leg Syndrome, and a U.S. Army grant), as well as assisting non-TSRI collaborators from The Sanford - Burnham Institute, The Salk Institute, and elsewhere.

In the study, Davis and his colleagues examined gastric tumors from nine human patients both before and after infusion with a drug — camptothecin — that was chemically bound to nanoparticles about 30 nanometers in sizIn the study, Davis and his colleagues examined gastric tumors from nine human patients both before and after infusion with a drug — camptothecin — that was chemically bound to nanoparticles about 30 nanometers in sizin size.

If the drug works in humans, Voot believes that — with adequate funding for this research — it could be available for heart attack patients within ten years.

The Food and Drug Administration in November approved the company's plans to test cells created from human embryonic stem cells on 12 patients suffering from each condition.

Moderna is pioneering messenger RNA Therapeutics ™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted.

In April of last year, the US Food and Drug Administration invited three large biotech companies - Geron, Advanced Cell Technology, and Novocell - to testify about how to safely test human embryonic stem cell (ESC) products in patientIn April of last year, the US Food and Drug Administration invited three large biotech companies - Geron, Advanced Cell Technology, and Novocell - to testify about how to safely test human embryonic stem cell (ESC) products in patientin patients.

All six patients suffered from end - stage heart disease and were enrolled in this first - in - human (FIH) clinical trial, approved by the U.S. Food and Drug Administration in late 2015.

Leveraging Moderna's messenger RNA Therapeutics ™ platform, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, Onkaido plans to rapidly turn scientific innovation into cancer therapies that can make a real difference for patients.

I hope in the next year we'll be able to develop and report on a method that allows the creation of billions of human beta cells that can then be used in two contexts; one, for transplantation into diabetics, and the other; using iPS cells from patients, for drug screening..

«Ultimately, we have to get a human model for human diseases so that we can expand human experimental biology in an ethical way and ensure that better, safer drugs get to patients faster,» he says.

• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study

In fact, so far, no drug that slowed neurodegeneration in a mouse model has worked when tested in adult human patientIn fact, so far, no drug that slowed neurodegeneration in a mouse model has worked when tested in adult human patientin a mouse model has worked when tested in adult human patientin adult human patients.